VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock.

Several other research firms have also recently commented on VNRX. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a report on Wednesday, March 12th.

VolitionRx Stock Performance

Shares of VNRX opened at $0.56 on Thursday. VolitionRx has a one year low of $0.43 and a one year high of $1.02. The stock has a 50-day moving average price of $0.60 and a 200 day moving average price of $0.64. The company has a market capitalization of $51.61 million, a P/E ratio of -1.55 and a beta of 1.09.

Institutional Trading of VolitionRx

Institutional investors and hedge funds have recently bought and sold shares of the company. Northern Trust Corp increased its holdings in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares during the last quarter. Two Sigma Securities LLC bought a new position in VolitionRx during the fourth quarter worth $29,000. Millennium Management LLC acquired a new position in VolitionRx in the fourth quarter worth $36,000. Geode Capital Management LLC increased its stake in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after purchasing an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. raised its holdings in shares of VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares during the period. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.